Argenx Se (ARGX) Consolidated Net Income (2016 - 2026)
Argenx Se's (ARGX) quarterly Consolidated Net Income came in at $482.0 million in Q2 2026, up 248.37% YoY from $138.4 million in Q2 2025, and up 27.51% on a QoQ basis from $378.0 million in Q1 2026.
Argenx Se (ARGX) Consolidated Net Income (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Consolidated Net Income data on file, last reported at $482.0 million in Q2 2026.
- Quarterly Consolidated Net Income rose 248.37% year-over-year to $482.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 51.26% YoY) and the FY2025 annual result came in at $1.3 billion, down 17.42% from the prior year.
- Consolidated Net Income rose to $482.0 million in Q2 2026, from $378.0 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $771.5 million in Q4 2024 to a low of -$241.3 million in Q1 2022.
- A 5-year average of $111.0 million and a median of $97500.0 in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 1435.49% — and 2024, when it jumped 877.94%.
- Tracing ARGX's Consolidated Net Income over 5 years: stood at -$38.6 million in 2022, then plunged by 156.84% to -$99.2 million in 2023, then jumped by 877.94% to $771.5 million in 2024, then slumped by 30.92% to $532.9 million in 2025, then decreased by 9.56% to $482.0 million in 2026.
- The last three Consolidated Net Income figures came in at $482.0 million (Q2 2026), $378.0 million (Q1 2026), and $532.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 482.00 Mn |
| Mar 31, 2026 | 378.00 Mn |
| Dec 31, 2025 | 532.95 Mn |
| Sep 30, 2025 | 427.85 Mn |
| Jun 30, 2025 | 138.36 Mn |
| Mar 31, 2025 | 202.47 Mn |
| Dec 31, 2024 | 771.50 Mn |
| Sep 30, 2024 | 91.41 Mn |
| Jun 30, 2024 | 29.07 Mn |
| Mar 31, 2024 | -61.60 Mn |
| Dec 31, 2023 | -99.17 Mn |
| Sep 30, 2023 | -72.64 Mn |
| Jun 30, 2023 | -94.37 Mn |
| Mar 31, 2023 | -28.87 Mn |
| Dec 31, 2022 | -38.61 Mn |
| Sep 30, 2022 | -235.04 Mn |
| Jun 30, 2022 | -183.57 Mn |
| Mar 31, 2022 | -241.26 Mn |
| Dec 31, 2021 | 251.94 Mn |
| Sep 30, 2021 | -228.12 Mn |